Eledon Pharmaceuticals(ELDN) - 2024 Q4 - Annual Results

Exhibit 99.1 Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial Results Tegoprubart used as a key component of immunosuppression regimen in the second transplant of a genetically modified pig kidney into a human conducted at Massachusetts General Hospital Announced positive initial data from first three subjects with type 1 diabetes treated with tegoprubart as part of immunosuppression regimen following islet transplantation in investigator-initiated trial at UChicago M ...